CMP8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: CMP8
• 英文别名: 9a-(4-chlorobenzyl)-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-1,2,9,9atetrahydro-3H-fluoren-3-one；9a-(4-Chlorobenzyl)-7-hydroxy-4-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-9,9a-dihydro-1H-fluoren-3(2H)-one；9a-[(4-chlorophenyl)methyl]-7-hydroxy-4-[4-(2-piperidin-1-ylethoxy)phenyl]-2,9-dihydro-1H-fluoren-3-one
• 化学式: C₃₃H₃₄ClNO₃
• 分子量: 528.091
• InChiKey: YHOXIEXEPIIKMD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.6
• 重原子数：
  38
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  CMP8 、 琥珀酸单[2-[(2-甲基-丙烯酰基)氧]乙基]酯 在 4-二甲氨基吡啶 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.67h， 以80%的产率得到
  参考文献：
  名称：

  CELL BASED METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME

  摘要：

  本文提供了经过工程改造的细胞以及用于工程改造细胞以传递治疗剂的方法，例如小分子、肽或其他药物，以治疗细胞或组织。

  公开号：

  US20200405881A1
• 作为产物：
  描述：

  N-羟乙基哌啶 在 盐酸 、 三氯化铝 、 偶氮二甲酸二异丙酯 、 异丙硫醇 、 三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 9.0h， 生成 CMP8
  参考文献：
  名称：

  A Structure-Guided Approach to an Orthogonal Estrogen-Receptor-Based Gene Switch Activated by Ligands Suitable for in Vivo Studies

  摘要：

  A strategy to obtain a fully orthogonal estrogen-receptor-based gene switch responsive to molecules with acceptable pharmacological properties is presented. From a series of tetrahydrofluorenones active on the wild-type estrogen receptor (ER) an inactive analogue is chosen as a new lead compound. Coevolution of receptor mutants and ligands leads to an ER-based gene switch suitable for studies in animal models.

  DOI：

  10.1021/jm060516e

文献信息

• CELL BASED METHODS AND COMPOSITIONS FOR THERAPEUTIC AGENT DELIVERY AND TREATMENTS USING SAME
  申请人：UNIVERSITY OF WASHINGTON

  公开号：US20200405881A1

  公开（公告）日：2020-12-31

  Provided herein are engineered cells and methods for engineering cells to deliver a therapeutic agent, e.g., a small molecule, peptide or other drug, to a cell or tissue to be treated.

  本文提供了经过工程改造的细胞以及用于工程改造细胞以传递治疗剂的方法，例如小分子、肽或其他药物，以治疗细胞或组织。
• Orthogonal gene switches
  申请人：Ciliberto Gennaro

  公开号：US20070087346A1

  公开（公告）日：2007-04-19

  The present invention relates to an orthogonal gene switch for regulating the expression of a desired gene. The gene switch comprises a chimeric transcription factor that does not respond to endogenous ligands, and a ligand that is capable of activating the chimeric transcription factor but not endogenous transcription factors. The present invention also relates to the method of constructing the orthogonal gene switch.

  本发明涉及一种正交基因开关，用于调节所需基因的表达。该基因开关包括一个嵌合转录因子，不响应内源性配体，以及一种配体，能够激活嵌合转录因子，但不能激活内源性转录因子。本发明还涉及构建正交基因开关的方法。
• Smart CAR devices and DE CAR polypeptides for treating disease and methods for enhancing immune responses
  申请人：Chimera Bioengineering, Inc.

  公开号：US11052111B2

  公开（公告）日：2021-07-06

  In an aspect, the present invention relates generally to the field of treating disease with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices. The present invention also relates generally to the genetic modification of cytotoxic T-lymphocytes to reduce target cell killing by apoptosis and/or increase production of lytic proteins at desired times. In an aspect, the invention relates to the use of these genetically modified T-lymphocytes and/or natural killer cells with CAR devices, Smart CAR devices, DE CAR devices, and/or Smart-DE CAR devices to enhance the immune response against a disease.

  在一个方面，本发明总体上涉及用CAR装置、智能CAR装置、DE CAR装置和/或智能-DE CAR装置治疗疾病的领域。本发明一般还涉及细胞毒性 T 淋巴细胞的基因修饰，以减少通过凋亡杀死靶细胞和/或在所需时间增加裂解蛋白的产生。在一个方面，本发明涉及将这些基因修饰的 T 淋巴细胞和/或自然杀伤细胞与 CAR 装置、Smart CAR 装置、DE CAR 装置和/或 Smart-DE CAR 装置一起使用，以增强针对疾病的免疫反应。
• Smart car devices, DE car polypeptides, side CARs and uses thereof
  申请人：Chimera Bioengineering, Inc.

  公开号：US11530272B2

  公开（公告）日：2022-12-20

  RNA Control Devices and/or destabilizing elements (DE) can regulate the expression of Chimeric Antigen Receptors (CARs) in eukaryotic cells. More specifically, DEs, RNA Control Devices, and/or side-CARs can be used with small molecule ligands to regulate the expression of Chimeric Antigen Receptors. These DE-CARs, Smart CARs (Smart=small molecule actuatable RNA trigger), Smart-DE-CARs, and/or Side-CARs can be used in the treatment of disease.

  RNA 控制装置和/或失稳元件（DE）可以调节真核细胞中嵌合抗原受体（CAR）的表达。更具体地说，DE、RNA 控制装置和/或侧 CAR 可与小分子配体一起用于调节嵌合抗原受体的表达。这些 DE-CAR、Smart CAR（Smart=小分子可激活的 RNA 触发器）、Smart-DE-CAR 和/或 Side-CAR 可用于治疗疾病。
• Destabilizing Domains Derived from the Human Estrogen Receptor
  作者：Yusuke Miyazaki、Hiroshi Imoto、Ling-chun Chen、Thomas J. Wandless

  DOI：10.1021/ja209933r

  日期：2012.3.7

  Methods to rapidly and reversibly perturb the functions of specific proteins are desirable tools for studies of complex biological processes. We have demonstrated an experimental strategy to regulate the intracellular concentration of any protein of interest by using an engineered destabilizing protein domain and a cell-permeable small molecule. Destabilizing domains have general utility to confer instability to a wide range of proteins including integral transmembrane proteins. This study reports a destabilizing domain system based on the ligand binding domain of the estrogen receptor that can be regulated by one of two synthetic ligands, CMP8 or 4-hydroxytamoxifen.